Group 1 - ICU Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, with their presentation scheduled for January 14, 2026, at 1:30 p.m. PT [1] - The presentation will be available via a live webcast on the company's website, with a replay option also provided [2] - ICU Medical is recognized as a global leader in infusion systems and critical care products, focusing on quality, innovation, and value for clinical customers [3]

Core Insights - Boston Scientific's Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% from 2026 to 2028, with expectations to exceed 10% average organic revenue growth [1] - The Electrophysiology (EP) business is anticipated to grow approximately 15% over the long-range plan, driven by market share gains and expansion into new areas [1][8] - The WATCHMAN device is the leading percutaneous left atrial appendage closure (LAAC) device globally, with a long-term growth outlook of over 20% contingent on trial outcomes [2][8] - The CRM DX business is expected to grow about 4% over the long-range plan, supported by recent investments and new product launches [3] - The Interventional Cardiology Therapies (ICTx) segment is projected to achieve 10% growth, particularly in emerging markets [4][8] - The Peripheral Interventions, Interventional Oncology, and Embolics businesses collectively represent a $11 billion market, with expected growth around 7% [4] Competitive Landscape - Medtronic's Diabetes business is preparing for an IPO, while its Hugo robotic-assisted surgery system has received FDA approval for urologic procedures [5] - Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion, enhancing its portfolio in prostate cancer therapies [6] Financial Performance - Boston Scientific shares have increased by 7.5% over the past year, outperforming the industry average of 1.7% [7] - The company's forward five-year Price-to-Earnings (P/E) ratio stands at 27.81, above both its median and the industry average [9] Earnings Estimates - Current earnings estimates for Boston Scientific indicate a projected earnings per share of $3.04 for the year ending December 2025, increasing to $3.45 for December 2026 [11]

About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a n ...

Market Performance - US stocks gained over 8% in the third quarter of 2025, as measured by the Russell 3000 Index, with small-cap stocks rising more than 12% [1] - Large-cap stocks increased by about 8%, while mid-cap stocks saw a gain of 5% [1] Diamond Hill Mid Cap Strategy Performance - The strategy underperformed the Russell Midcap Index in Q3 2025, returning 4.49% net compared to 5.33% for the Index [1] The Cooper Companies, Inc. Overview - The Cooper Companies, Inc. (NASDAQ:COO) manufactures and markets contact lenses through its CooperVision and CooperSurgical segments [2] - The one-month return for The Cooper Companies, Inc. was 8.74%, but its shares lost 10.29% of their value over the last 52 weeks [2] - As of December 30, 2025, the stock closed at $82.47 per share, with a market capitalization of $16.396 billion [2] Investment Insights - The Diamond Hill Mid Cap Strategy initiated several new positions in Q3 2025, including The Cooper Companies, Inc. [3] - Despite the overall market rise, the company is viewed as undervalued relative to its long-term growth outlook [3] - The Cooper Companies, Inc. had consolidated revenues up 4.6% year over year to a quarterly record of $1.065 billion in Q4 2025 [4] - The number of hedge fund portfolios holding The Cooper Companies, Inc. increased from 48 to 56 in the third quarter [4]

Core Insights - Profusa, Inc. has established a new distributor partnership with MedSell in France to commercialize Lumee™ Oxygen tissue monitoring, expanding its reach in the European market [1][2] - The partnership aims to address the needs of approximately 200,000 annual Critical Limb Threatening Ischemia (CLTI) cases in the European Union, with MedSell focusing on hospital and outpatient care settings [1][2] - The collaboration with MedSell complements an existing partnership with a leading vascular surgeon in France, who accounts for about 8% of all CLTI cases in the country [2] Company Strategy - Profusa aims to achieve $200 to $250 million in revenue by 2030, with projected revenues of $0.5 to $2 million in 2026 and $9 to $13 million in 2027 [3] - The company is focused on executing its commercial strategies, including the introduction of Lumee Oxygen monitoring in Europe starting in Q2 2026, with plans to enter the US market in 2027 [3] - Profusa emphasizes the importance of making its oxygen tissue monitoring platform accessible in both clinical and home settings to enhance patient outcomes and reduce healthcare costs [3] Product Overview - Lumee Oxygen tissue monitoring is designed to measure tissue oxygen perfusion before and during surgical procedures, as well as during follow-up care, addressing a critical unmet clinical need [2] - The device is expected to provide significant value to clinicians by supporting decision-making and patient monitoring throughout the treatment pathway [2] - Profusa's technology is part of a broader initiative to develop tissue-integrated sensors that continuously transmit actionable medical data [4]

Core Insights - Shenzhen has produced a number of globally impactful companies, showcasing a shift from "Made in China" to "Created in China" [2] - The 45th anniversary of Shenzhen Special Economic Zone marks a significant milestone in its rapid modernization and brand development [2][3] - The "Shenzhen Brand Development White Paper (1980-2025)" outlines the evolution of Shenzhen's brands and their internal logic and success factors [3][5] Group 1: Brand Evolution - Shenzhen's brand journey reflects a transition from manufacturing to innovation, with key phases including the emergence of local brands in the 1980s and 1990s, and the rise of autonomous brands in the early 2000s [7][10] - The current phase is characterized by cluster upgrades, with companies like Tencent, BYD, and DJI leading in various sectors [8][10] - As of now, Shenzhen has cultivated 1,220 notable local brands, including 13 billion-level brands and 7 trillion-level brands, with Tencent, Ping An, and Huawei each exceeding a brand value of 490 billion [10][11] Group 2: Economic Contributions - The 1,220 notable brands contribute 47.97% of the city's sales, 42.05% of tax revenue, and 32.87% of exports, serving as the backbone of Shenzhen's high-quality economic development [11] - These brands span critical sectors such as electronics, renewable energy, biomedicine, high-end equipment, financial services, and digital economy, forming a robust industrial structure [11] Group 3: Brand Development Factors - Shenzhen's brand success is attributed to a unique ecosystem supported by policy innovation, technological advancement, and collaborative industrial frameworks [15][16][19] - The government has played a crucial role in creating a conducive environment for brand growth through targeted policies and regulatory frameworks [16] - Innovation drives brand competitiveness, with companies investing over 10% of their annual revenue in R&D, fostering a comprehensive innovation ecosystem [17] Group 4: Global Expansion and Responsibility - Shenzhen brands have established clear pathways for international expansion, evolving from processing trade to localized operations and global standardization [20] - Social responsibility is ingrained in the corporate strategy, enhancing brand value and sustainability through practices like tax compliance and community support [21] Group 5: Future Outlook - The release of the white paper is a significant step in documenting Shenzhen's brand journey and providing strategic guidance for future brand development [31] - Shenzhen's brands are expected to continue thriving in emerging sectors like digital and low-altitude economies, contributing to the global narrative of Chinese brands [33][34]

Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant financial losses for investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Inspire securities between August 6, 2024, and August 4, 2025 [1]. - Allegations include that the company failed to disclose poor demand for its product and had surplus inventory, which affected the transition to the new treatment [1]. - The lawsuit claims that Inspire Medical did not complete essential tasks for a successful product launch, contrary to their public assurances [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers [2]. - The company admitted that software updates necessary for billing were not effective until July 1, leading many centers to continue using an earlier version of the product [2]. - Following the announcement, Inspire's stock price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 per share [2].

Corporate Update - MedMira Inc. reported its financial results for the quarter ended October 31, 2025 [1] - The company received Health Canada approval for its Reveal® TP (Syphilis) rapid test in Q1 FY2026 [1]

Core Viewpoint - The global IPO market is expected to fully recover by 2025, primarily supported by a fundamental shift in the global liquidity environment as major central banks, led by the Federal Reserve, begin to lower interest rates after a period of aggressive rate hikes since 2022 [2] Group 1: Market Dynamics - The Hong Kong stock market has regained its position as the top global IPO fundraising market, with total IPO fundraising expected to reach HKD 2787.03 billion (approximately USD 359 billion), surpassing the Nasdaq's USD 258 billion, marking the highest level since 2021 [6] - The influx of capital from both domestic and international investors has created a dual-driven dynamic in the Hong Kong market, providing significant liquidity support for large IPO projects [2][4] - The number of IPO applications processed by the Hong Kong Stock Exchange has surged to 331, up from 84 at the beginning of the year, indicating a potential acceleration in IPO transactions towards the end of the year [4][19] Group 2: Notable IPOs - The largest IPO in Hong Kong this year was by Contemporary Amperex Technology Co., Ltd. (宁德时代), raising HKD 310.06 billion (approximately USD 39.88 billion) with a cumulative increase of 89.28% since listing [12] - Other significant IPOs include Zijin Mining's spin-off, which raised HKD 249.84 billion (approximately USD 32.14 billion), and the listing of Seres, which raised HKD 131.76 billion (approximately USD 16.95 billion) [12] Group 3: Future Outlook - The IPO market is expected to become more crowded in 2026, with a significant number of companies, particularly in the technology and innovation sectors, preparing for potential listings [16][18] - Major companies like SpaceX and AI leaders such as OpenAI and Anthropic are anticipated to initiate IPO processes, which could lead to the largest IPO wave in history [18] - The Hong Kong market may face challenges due to a backlog of IPO applications, which could exacerbate competition in the global IPO landscape [19][20]

Core Viewpoint - Profound Medical Corp. has successfully completed a private placement of common shares, raising approximately US$6.45 million to support its business expansion and development efforts [1][2]. Group 1: Offering Details - The company issued a total of 921,428 common shares at a price of US$7.00 per share [1]. - The shares are subject to a hold period of four months plus one day from the closing date under Canadian securities laws [2]. - The net proceeds from the offering will be allocated for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes [2]. Group 2: Regulatory Information - The securities offered have not been registered under the U.S. Securities Act and cannot be sold in the U.S. without registration or an applicable exemption [3]. - The company plans to file a registration statement with the U.S. Securities and Exchange Commission within four months from the closing date of the offering [3]. Group 3: Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free therapies for tissue ablation [5]. - The company is commercializing TULSA-PRO, a technology designed for the treatment of various prostate conditions, which is CE marked, Health Canada approved, and FDA 510(k) cleared [6]. - Profound is also developing Sonalleve, a therapeutic platform for treating uterine fibroids and other conditions, which has received CE marking and FDA approval under a Humanitarian Device Exemption [7].